Radiosensitization of prostate cancer by soy isoflavones

Current Cancer Drug Targets

Volumn 7, Issue 8, 2007, Pages 759-765

  Raffoul, Julian J ^a   Sarkar, Fazlul H ^a   Hillman, Gilda G ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 515 Hudson Webber Cancer Research Center ^*  (United States)

Author keywords

APE1 Ref 1; Apoptosis; Genistein soy; NF kappa B; Prostate cancer; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DAIDZEIN; GENISTEIN; GLYCITEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE DERIVATIVE; REDOX EFFECTOR FACTOR 1;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL DEATH; CELL SURVIVAL; CHEMOPROPHYLAXIS; DIET; DOWN REGULATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; NONHUMAN; PROSTATE CANCER; RADIATION INJURY; RADIOSENSITIZATION; REVIEW; RISK REDUCTION;

ANIMALS; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; SOYBEANS;

EID: 37449004232     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907783220408     Document Type: Review

References (92)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer Statistics, 2007. CA Cancer J. Clin. 2007, 57, 43-66.
2. Zietman, A. L.; Shipley, W. U.; Willett, C. G. Residual disease after radical surgery or radiation therapy for prostate cancer. Cancer 1993, 71, 959-969.
3. Forman, J. D. Neutron radiation for prostate cancer. Prostate J. 1999, 1, 8-14.
4. Clinton, S. K.; Giovannucci, E. D. nutrition, and prostate cancer. Annu. Rev. Nutr. 1998, 18, 413-440.
5. Giovannucci, E. Nutritional factors in human cancers. Adv. Exp. Med. Biol. 1999, 472, 29-42.
6. Greenwald, P. Clinical trials in cancer prevention: current results and perspectives for the future. J. Nutr. 2004, 134, 3507S-3512S.
7. Bostwick, D. G.; Burke, H. B.; Djakiew, D.; Euling, S.; Ho, S. M.; Landolph, J.; Morrison, H.; Sonawane, B.; Shifflett, T.; Waters, D. J.; Timms, B. Human prostate cancer risk factors. Cancer 2004, 101, 2371-2490.
8. Sarkar, F. H.; Li, Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res. 2006, 66, 3347-3350.
9. Hebert, J. R.; Hurley, T. G.; Olendzki, B. C.; Teas, J.; Ma, Y.; Hampl, J. S. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J. Natl. Cancer Inst. 1998, 90, 1637-1647.
10. Knight, D. C.; Eden, J. A. A review of the clinical effects of phytoestrogens. Obstet. Gynecol. 1996, 87, 897-904.
11. Barnes, S.; Prasain, J.; D'Alessandro, T.; Wang, C.; Zhang, H.; Kim, H. Soy Isoflavone. In: Heber, D.; Blackburn, G. L.; Go, V. L. W.; Milner, J., Eds. Nutritional Oncology, 2nd ed., Academic Press: St. Louis, 2006, pp. 559-571.
12. Norman, H. A.; Go, V. L.; Butrum, R. R. Review of the international research conference on food, nutrition, and cancer, 2004. J. Nutr. 2004, 134, 3391S-3393S.
13. Sarkar, F. H.; Li, Y. Mechanisms of cancer chemoprevention by soy isoflavone genistein. Cancer Metastasis Rev. 2002, 21, 265-80.
14. Sarkar, F. H.; Li, Y. Soy isoflavones and cancer prevention. Cancer Invest. 2003, 21, 744-757.
15. Sarkar, F. H.; Li, Y. The role of isoflavones in cancer chemoprevention. Front Biosci. 2004, 9, 2714-2724.
16. Ravindranath, M. H.; Muthugounder, S.; Presser, N.; Viswanathan, S. Anticancer therapeutic potential of soy isoflavone, genistein. Adv. Exp. Med. Biol. 2004, 546, 121-165.
17. WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr. Cancer 1998, 32, 123-131.
18. Davis, J. N.; Kucuk, O.; Sarkar, F. H. Genistein inhibits NF-kappa B activation in prostate cancer cells. Nutr. Cancer 1999, 35, 167-174.
19. Hillman, G. G.; Forman, J. D.; Kucuk, O.; Yudelev, M; Maughan, R. L.; Rubio, J.; Layer, A.; Tekyi-Mensah, S.; Abrams, J.; Sarkar, F. H. Genistein potentiates the radiation effect on prostate carcinoma cells. Clin. Cancer Res. 2001, 7, 382-390.
20. Raffoul, J. J.; Wang, Y.; Kucuk, O.; Forman, J. D.; Sarkar, F. H.; Hillman, G. G. Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 2006, 6, 107.
21. Adlercreutz, H.; Markkanen, H.; Watanabe, S. Plasma concentration of phyto-oestrogens in Japanese men. Lancet 1993, 342, 1209-1210.
22. Xu, X.; Harris, K. S.; Wang, H. J.; Murphy, P. A.; Hendrich, S. Bioavailibility of soybean isoflavones depends upon gut microflora in women. J. Nutr. 1995, 125, 2307-2315.
23. van Rijn, J.; van den Berg, J. Flavonoids as enhancers of x-ray-induced cell damage in hepatoma cells. Clin. Cancer Res. 1997, 3, 1775-1779.
24. Akimoto, T.; Nonaka, T.; Ishikawa, H.; Sakurai, H.; Saitoh, J. I.; Takahashi, T.; Mitsuhashi, N. Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways. Int. J. Radiat. Oncol. Biol. Phys. 2001, 50, 195-201.
25. Yan, S. -X.; Ejima, Y.; Sasaki, R.; Zheng, S. -S.; Demizu, Y.; Soejima, T.; Sugimura, K. Combination of genistein with ionizing radiation on androgen-independent prostate cancer cells. Asian J. Androl. 2004, 6, 285-290.
26. Yashar, C. M.; Spanos, W. J.; Taylor, D. D.; Gercel-Taylor, C. Potentiation of the radiation effect with genistein in cervical cancer cells. Gynecol. Oncol. 2005, 99, 199-205.
27. Zhang, B.; Liu, J. Y.; Pan, J. S.; Han, S. P.; Yin, X. X.; Wang, B.; Hu, G. Combined treatment of ionizing radiation with genistein on cervical cancer HeLa cells. J. Pharmacol. Sci. 2006, 102, 129-135.
28. Pawlik, T. M.; Keyomarsi, K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 928-942.
29. Geldof, A. A.; Plaizier, M. A.; Duivenvoorden, I.; Ringelberg, M.; Versteegh, R. T.; Newling, D. W.; Teule, G. J. Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. J. Cancer Res. Clin. Oncol. 2003, 129, 175-182.
30. Hillman, G. G.; Wang, Y.; Kucuk, O.; Che, M.; Doerge, D. R.; Yudelev, M.; Joiner, M. C.; Marples, B.; Forman, J. D.; Sarkar, F. H. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol. Cancer Ther. 2004, 3, 1271-1279.
31. Wang, Y.; Raffoul, J. J.; Che, M.; Doerge, D. R.; Joiner, M. C.; Kucuk, O.; Sarkar, F. H.; Hillman, G. G. Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat. Res. 2006, 166, 73-80.
32. Hillman, G. G.; Wang, Y.; Che, M.; Raffoul, J. J.; Yudelev, M.; Kucuk, O.; Sarkar, F. H. Progression of renal cell carcinoma is inhibited by genistein and radiation in an orthotopic model. BMC Cancer 2001, 7, 4.
33. Mentor-Marcel, R.; Lamartiniere, C. A.; Eltoum, I. E.; Greenberg, N. M.; Elgavish, A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 2001, 61, 6777-6782.
34. Aronson, W. J.; Tymchuk, C. N.; Elashoff, R. M.; McBride, W. H.; McLean, C.; Wang, H.; Heber, D. Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. Nutr. Cancer 1999, 35, 130-136.
35. Lamartiniere, C. A.; Murrill, W. B.; Manzolillo, P. A.; Zhang, J. X.; Barnes, S.; Zhang, X.; Wei, H.; Brown, N. M. Genistein alters the ontogeny of mammary gland development and protects against chemically-induced mammary cancer in rats. Proc. Soc. Exp. Biol. Med. 1998, 217, 358-364.
36. Lamartiniere, C. A.; Cotroneo, M. S.; Fritz, W. A.; Wang, J.; Mentor-Marcel, R.; Elgavish, A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J. Nutr. 2002, 132, 552S-558S.
37. Onozawa, M.; Kawamori, T.; Baba, M.; Fukuda, K.; Toda, T.; Sato, H.; Ohtani, M.; Akaza, H.; Sugimura, T.; Wakabayashi, K. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn. J. Cancer Res. 1999, 90, 393-398.
38. Zhou, J. R.; Gugger, E. T.; Tanaka, T.; Guo, Y.; Blackburn, G. L.; Clinton, S. K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice. J. Nutr. 1999, 129, 1628-1635.
39. Zhou, J. R.; Yu, L.; Zhong, Y.; Nassr, R. L.; Franke, A. A.; Gaston, S. M.; Blackburn, G. L. Inhibition of orthotopic growth and metastasis of androgensensitive human prostate tumors in mice by bioactive soybean components. Prostate 2002, 53, 143-153.
40. Rao, C. V.; Rivenson, A.; Simi, B.; Zang, E.; Hamid, R.; Kelloff, G. J.; Steele, V.; Reddy, B. S. Enhancement of experimental colon carcinogenesis by dietary 6-phenylhexyl isothiocyanate. Cancer Res. 1995, 55, 4311-4318.
41. Cohen, L. A.; Zhao, Z.; Pittman, B.; Scimeca, J. Effect of soy protein isolate and conjugated linoleic acid on the growth of Dunning R-3327-AT-1 rat prostate tumors. Prostate 2003, 54, 169-180.
42. Wietrzyk, J.; Mazurkiewicz, M.; Madej, J.; Dzimira, S.; Grynkiewicz, G.; Radzikowski, C.; Opolski, A. Genistein alone or combined with cyclophosphamide may stimulate 16/C transplantable mouse mammary cancer growth. Med. Sci. Monit. 2004, 10, BR414-BR419.
43. Hussain, M.; Banerjee, M.; Sarkar, F. H.; Djuric, Z.; Pollak, M. N.; Doerge, D.; Fontana, J.; Chinni, S.; Davis, J.; Forman, J.; Wood, D. P.; Kucuk, O. Soy isoflavones in the treatment of prostate cancer. Nutr. Cancer 2003, 47, 111-117.
44. Singh, A. V.; Franke, A. A.; Blackburn, G. L.; Zhou, J. R. Soy phytochemicals prevent orthotopic growth and metastasis of bladder cancer in mice by alterations of cancer cell proliferation and apoptosis and tumor angiogenesis. Cancer Res. 2006, 66, 1851-1858.
45. Raffoul, J. J.; Banerjee, S.; Che, M.; Knoll, Z. E.; Doerge, D. R.; Abrams, J.; Kucuk, O.; Sarkar, F. H.; Hillman, G. G. Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int. J. Cancer 2007, 120, 2491-2498.
46. Vantyghem, S. A.; Wilson, S. M.; Postenka, C. O.; Al-Katib, W.; Tuck A. B.; Chambers, A. F. Dietary Genistein reduces metastasis in a Postsurgical Orthotopic breast cancer model. Cancer Res. 2005, 65, 3396-3403.
47. Sasamura, H.; Takahashi, A.; Yuan, J.; Kitamura, H.; Masumori, N.; Miyao, N.; Itoh, N.; Tsukamoto, T. Antiproliferative and antiangiogenic activities of genistein in human renal cell carcinoma. Urology 2004, 64, 389-393.
48. Subarsky, P.; Hill, R. P. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 2003, 20, 237-250.
49. Pumford, S. L.; Morton, M. M.; Turkes, A.; Griffiths, K. Determination of the isoflavonoids genistein and daidzein in biological samples by gas chromatography-mass spectrometry. Ann. Clin. Biochem. 2002, 39, 281-292.
50. Valentin-Blasini, L.; Blount, B. C.; Caudill, S. P.; Needham, L. L. Urinary and serum concentrations of seven phytoestrogens in a human reference population subset. J. Expo. Anal. Environ. Epidemiol. 2003, 13, 276-282.
51. Lee, M. M.; Gomez, S. L.; Chang, J. S.; Wey, M.; Wang, R. T.; Hsing, A. W. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol. Biomarkers Prev. 2003, 2, 665-668.
52. Greendale, G. A.; FitzGerald, G.; Huang, M. H.; Sternfeld, B.; Gold, E.; Seeman, T.; Sherman, S.; Sowers, M. Dietary soy isoflavones and bone mineral density: results from the study of women's health across the nation. Am. J. Epidemiol. 2002, 155, 746-754.
53. Raffoul, J. J.; Banerjee, S.; Singh-Gupta, V.; Knoll, Z. E.; Fite, A.; Zhang, H.; Abrams, J.; Sarkar, F. H.; Hillman, G. G. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res. 2007, 67, 2141-2149.
54. Storz, P.; Toker, A. NFκB signaling: an alternate pathway for oxidative stress responses. Cell Cycle 2003, 2, 9-10.
55. Lin, A.; Karin, M. NF-κB in cancer: a marked target. Semin. Cancer Biol. 2003, 13, 107-114.
56. Yamamoto, Y.; Gaynor, R. B. Role of the NFκB pathway in the pathogenesis of human disease states. Curr. Mol. Med. 2001, 1, 287-296.
57. Karin, M.; Cao, Y.; Greten, F. R.; Li, Z. W. NFκB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2002, 2, 301-310.
58. Karin, M. Nuclear factor-κB in cancer development and progression. Nature 2006, 441, 431-436.
59. Sweeney, C.; Li, L.; Shanmugam, R.; Bhat-Nakshatri, P.; Jayaprakasan, V.; Baldridge, L. A.; Gardner, T.; Smith, M.; Nakshatri, H.; Cheng, L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res. 2004, 10, 5501-5507.
60. Shukla, S.; MacLennan, G. T.; Fu, P.; Patel, J.; Marengo, S. R.; Resnick, M. I.; Gupta, S. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004, 6, 390-400.
61. Li, Y.; Sarkar, F. H. Inhibition of nuclear factor kappaB activation in PC3 cells by genistein is mediated via Akt signaling pathway. Clin. Cancer Res. 2002, 8, 2369-2377.
62. Pajonk, F.; Pajonk, K.; McBride, W. H. Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J. Natl. Cancer Inst. 1999, 91, 1956-1960.
63. Kim, K. M.; Zhang, Y.; Kim, B. Y.; Jeong, S. J.; Lee, S. A.; Kim, G. D.; Dritschilo, A.; Jung, M. The p65 subunit of nuclear factor-kappaB is a molecular target for radiation sensitization of human squamous carcinoma cells. Mol. Cancer Ther. 2004, 3, 693-698.
64. Wang, T.; Hu, Y. C.; Dong, S.; Fan, M.; Tamae, D.; Ozeki, M.; Gao, Q.; Gius, D.; Li, J. J. Co-activation of ERK, NF-kappa B and GADD45beta in response to ionizing radiation. J. Biol. Chem. 2005, 280, 12593-12601.
65. Shimizu, N.; Sugimoto, K.; Tang, J.; Nishi, T.; Sato, I.; Hiramoto, M.; Aizawa, S.; Hatakeyama, M.; Ohba, R.; Hatori, H.; Yoshikawa, T.; Suzuki, F.; Oomori, A.; Tanaka, H.; Kawaguchi, H.; Watanabe, H.; Handa, H. High-performance affinity beads for identifying drug receptors. Nat. Biotechnol. 2000, 18, 877-881.
66. Nishi, T.; Shimizu, N.; Hiramoto, M.; Sato, I.; Yamaguchi, Y.; Hasegawa, M.; Aizawa, S.; Tanaka, H.; Kataoka, K.; Watanabe, H.; Handa, H. Spatial redox regulation of a critical cysteine residue of NF-kappa B in vivo. J. Biol. Chem. 2002, 277, 44548-44556.
67. Hall, J. L.; Wang, X.; Van Adamson, Zhao, Y.; Gibbons, G. H. Overexpression of Ref-1 inhibits hypoxia and tumor necrosis factor-induced endothelial cell apoptosis through nuclear factor-kappab-independent and - dependent pathways. Circ. Res. 2001, 88, 1247-1253.
68. Guan, Z.; Basi, D.; Li, Q.; Mariash, A.; Xia, Y. F.; Geng, J. G.; Kao, E.; Hall, J. L. Loss of redox factor 1 decreases NF-kappaB activity and increases susceptibility of endothelial cells to apoptosis. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 96-101.
69. Robson, C. N.; Hickson, I. D. Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E.coli xth (exonuclease III) mutants. Nucleic. Acids Res. 1991, 19, 5519-5523.
70. Xanthoudakis, S.; Curran, T. Identification and characterization of Ref-1, a nuclear rotein that facilitates AP-1 DNA binding activity. EMBO J. 1992, 11, 653-665.
71. Xanthoudakis, S.; Miao, G.; Wang, F.; Pan, Y. C.; Curran, T. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme. EMBO J. 1992, 11, 3323-3335.
72. Evans, A. R.; Limp-Foster, M.; Kelley, M. R. Going APE over Ref-1. Mutat. Res. 2000, 461, 83-108.
73. Raffoul, J. J.; Cabelof, D. C.; Nakamura, J.; Meira, L. B.; Friedberg, E. C.; Heydari, A. R. Apurinic/apyrimidinic endonuclease (APE/REF-1) haploinsufficient mice display tissue-specific differences in DNA polymerase beta-dependent base excision repair. J. Biol. Chem. 2004, 279, 18425-18433.
74. Herring, C. J.; West, C. M.; Wilks, D. P.; Davidson, S. E.; Hunter, R. D.; Berry, P.; Forster, G.; MacKinnon, J.; Rafferty, J. A.; Elder, R. H.; Hendry, J. H.; Margison, G. P. Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers. Br. J. Cancer 1998, 78, 1128-1133.
75. Robertson, K. A.; Bullock, H. A.; Xu, Y.; Tritt, R.; Zimmerman, E.; Ulbright, T. M.; Foster, R. S.; Einhorn, L. H.; Kelley, M. R. Altered expression of Ape1/ref-1 in germ cell tumors and over-expression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res. 2001, 61, 2220-2225.
76. Wang, D.; Luo, M.; Kelley, M. R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol. Cancer Ther. 2004, 3, 679-686.
77. Tell, G.; Damante, G.; Caldwell, D.; Kelley, M. R. The intracellular localization of APE1/Ref-1: more than a passive phenomenon? Antioxid. Redox Signal. 2005, 7, 367-384.
78. Garg, A. K.; Buchholz, T. A.; Aggarwal, B. B. Chemosensitization and Radiosensitization of Tumors by Plant Polyphenols. Antioxid. Redox. Signal. 2005, 7, 1630-1647.
79. Chendil, D.; Ranga, R. S.; Meigooni, D.; Satishkumar, S.; Ahmed, M. M. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 2004, 23, 1599-1607.
80. Li, M.; Zhang, Z.; Hill, D. L.; Wang, H.; Zhang, R. Curcumin, a dietary component, has Anticancer, Chemosensitization, and Radiosensitization Effects by Down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 2007, 67, 1988-1996.
81. Liao, H. F.; Kuo, C. D.; Yang, Y. C.; Lin, C. P.; Tai, H. C.; Chen, Y. Y.; Chen, Y. J. Resveratrol enhances radiosensitivity of human non-small cell lung cancer NCI-H838 cells accompanied by inhibition of nuclear factorkappa B activation. J. Radiat. Res. 2005, 46, 387-393.
82. Scarlatti, F.; Sala, G.; Ricci, C.; Maioli, C.; Milani, F.; Minella, M.; Botturi, M.; Ghidoni, R. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett. 2007, 253(1), 124-130.
83. Baatout, S.; Derradji, H.; Jacquet, P.; Ooms, D.; Michaux, A.; Mergeay, M. Enhanced radiation-induced apoptosis of cancer cell lines after treatment with resveratrol. Int. J. Mol. Med. 2004, 13, 895-902.
84. Xu, L.; Yang, D.; Wang, S.; Tang, W.; Liu, M.; Davis, M.; Chen, J.; Rae, J. M.; Lawrence, T.; Lippman, M. E. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol. Cancer Ther. 2005, 4, 197-205.
85. Weiss, J. F.; Landauer, M. R. Protection against ionizing radiation by antioxidant nutrients and phytochemicals. Toxicology 2003, 189, 1-20.
86. Messina, M.; Kucuk, O.; Lampe, J. W. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J. AOAC Int. 2006, 89, 1121-1134.
87. Yang, S.; Irani, K.; Heffron, S. E.; Jurnak, F.; Meyskens, F. L., Jr. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 2005, 4, 1923-1935.
88. Madhusudan, S.; Hickson, I. D. DNA repair inhibition: a selective tumour targeting strategy. Trends Mol. Med. 2005, 11, 503-511.
89. Kelley, M. R.; Cheng, L.; Foster, R.; Tritt, R.; Jiang, J.; Broshears, J.; Koch, M. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin. Cancer Res. 2001, 7, 824-830.
90. Gong, L.; Li, Y.; Nedeljkovic-Kurepa, A.; Sarkar, F. H. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene 2003, 22, 4702-4709.
91. Banerjee, S.; Zhang, Y.; Ali, S.; Bhuiyan, M.; Wang, Z.; Chiao, P. J.; Philip, P. A.; Abbruzzese, J.; Sarkar, F. H. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res. 2005, 65, 9064-9072.
92. Li, Y.; Ahmed, F.; Ali, S.; Philip, P. A.; Kucuk, O.; Sarkar, F. H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005, 65, 6934-6942.